PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.88%
Negative revenue growth while MCHP stands at 7.38%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-3.46%
Negative gross profit growth while MCHP is at 7.97%. Joel Greenblatt would examine cost competitiveness or demand decline.
-155.87%
Negative EBIT growth while MCHP is at 6.80%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-155.87%
Negative operating income growth while MCHP is at 6.80%. Joel Greenblatt would press for urgent turnaround measures.
-116.65%
Negative net income growth while MCHP stands at 12.27%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-116.07%
Negative EPS growth while MCHP is at 9.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-116.82%
Negative diluted EPS growth while MCHP is at 9.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.87%
Share reduction more than 1.5x MCHP's 3.37%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-0.32%
Reduced diluted shares while MCHP is at 3.37%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
5.33%
Dividend growth of 5.33% while MCHP is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-13.35%
Negative OCF growth while MCHP is at 91.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-23.08%
Negative FCF growth while MCHP is at 673.94%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
27.65%
10Y revenue/share CAGR under 50% of MCHP's 108.56%. Michael Burry would suspect a lasting competitive disadvantage.
12.23%
5Y revenue/share CAGR under 50% of MCHP's 108.56%. Michael Burry would suspect a significant competitive gap or product weakness.
-17.00%
Negative 3Y CAGR while MCHP stands at 108.56%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
23.67%
Below 50% of MCHP's 180.99%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
4.59%
3Y OCF/share CAGR under 50% of MCHP's 180.99%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-398.64%
Negative 10Y net income/share CAGR while MCHP is at 116.41%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-439.94%
Negative 5Y net income/share CAGR while MCHP is 116.41%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-244.17%
Negative 3Y CAGR while MCHP is 116.41%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
176.53%
10Y equity/share CAGR at 75-90% of MCHP's 229.37%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
178.97%
5Y equity/share CAGR at 75-90% of MCHP's 229.37%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
85.07%
Below 50% of MCHP's 229.37%. Michael Burry suspects a serious short-term disadvantage in building book value.
93.86%
Dividend/share CAGR of 93.86% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
30.11%
Dividend/share CAGR of 30.11% while MCHP is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
40.58%
3Y dividend/share CAGR of 40.58% while MCHP is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-3.45%
Firm’s AR is declining while MCHP shows 17.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.11%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-10.15%
Negative asset growth while MCHP invests at 10.93%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-7.23%
We have a declining book value while MCHP shows 25.93%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-16.54%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
169.45%
R&D growth drastically higher vs. MCHP's 7.57%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
16.62%
SG&A growth well above MCHP's 9.93%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.